Huntington's disease (HD) is a rare, inherited disorder that causes the progressive breakdown of nerve cells in the brain. It's a condition that's passed down in families from generation to ...

After seven decades with no advances in the treatment of the genetic disorder classic congenital adrenal hyperplasia (CAH), ...

Qure stock surges after FDA agrees on an accelerated approval pathway for its Huntington's disease treatment, AMT-130.

During the first 12 days of December, shares of uniQure rocketed 152% higher, and investors want to know if this stock has ...

Opens in a new tab or window Beta-blocker use was tied with slower symptom progression in people with early motor-manifest Huntington's disease. In a people with genetically confirmed premanifest ...

Qure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges ...

Maybe she would even bring awareness to this rare disease in some small way that contributes to its eventual cure. Therein lies my magic. It is not the Huntington’s itself that makes me powerful.

The FDA will allow uniQure NV to seek accelerated approval for its Huntington’s disease gene therapy more than doubled the ...

Study finds β-blockers may delay onset and slow progression of Huntington's disease, offering potential as a therapeutic strategy Study: β-Blocker Use and Delayed Onset and Progression of ...

The latest to haunt the brain and its nerve cells is Huntington’s disease (HD). But what is it actually? Decoding HD HD is a neurological condition that affects the brain, inducing the neurons ...

At the center of the deal is an experimental medicine, PTC518, which is currently being tested as a potential treatment for Huntington’s disease in ... target a range of rare illnesses, from ...